Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *